Acarbose is a pharmacologic drug currently employed in the treatment of subjects with diabetes due to its potential to inhibit α-amylase and α-glucosidase enzymes, thus reducing carbohydrate digestion, slowing down the absorption of carbohydrates, and decreasing postprandial insulin secretion, in addition to stimulating glucagon-like peptide (GLP-1) release [45]. This evidence concerns the gene INS and diabetes mellitus.